Appendix B: Panel Roster and Financial Disclosures
Invasive Mycoses
| Member | Institution | Financial Disclosure | |
|---|---|---|---|
| Company | Relationship | ||
| John Baddley | University of Maryland School of Medicine | Synexis | Research Support (paid to institution) |
| David Boulware | University of Minnesota Medical School | Appili Therapeutics Matinas BioPharma | Research Support (paid to institution) |
| Marisa Miceli | University of Michigan Medical School | SCYNEXIS F2G Mayne Pharma | Research Support (paid to institution) |
| SCYNEXIS | Data Safety Monitoring Board | ||
| Astellas Pharma | Consulting | ||
| John Perfect* | Duke University, School of Medicine | Pfizer | Advisory Board |
| George R. Thompson | University of California, Davis Medical Center | Amplyx Pharmaceuticals Astellas Pharm Cidara Therapeutics F2G Mayne Pharma | Scientific Advisory Board |
| * Section Group Lead Note: Members are required to update disclosures annually and to notify guideline staff of any relevant changes in status during the interim. | |||
Download Guidelines
- Section Only PDF (16.83 KB)
- Full Guideline PDF (6.02 MB)
- Tables Only PDF (1.18 MB)